2017
August
![]() © Patrick J. Lynch [CC BY 2.5]
| In a study it has been shown that the anti-inflammatory drug canakinumab can reduce cardiovascular risk independent of lowering cholesterol and lifestyle changes. This could provide a third line of treatment in the longer run. |